Scholarlink

<p>Melanoma is a highly aggressive malignancy in which dysregulated ubiquitin-dependent signaling contributes to tumor progression. <i>OTUD4</i> is frequently downregulated in melanoma, but the functional significance of this alteration remains unclear. Here, we identify OTUD4 as a dual-mode deubiquitinase that suppresses melanoma progression by coordinating K48- and K63-linked polyubiquitination. OTUD4 directly binds and stabilizes CYLD by counteracting K48-linked polyubiquitination, whereas it independently binds BCL3 and counteracts BCL3 K63-linked polyubiquitination. OTUD4 depletion promotes BCL3 ubiquitination and nuclear translocation in melanoma cells, leading to increased melanoma cell proliferation and tumor growth in clonogenic and xenograft assays. Clinically, expression of <i>OTUD4</i> and <i>CYLD</i> progressively decreases from normal skin through benign nevi to melanoma, with a further reduction in highly metastatic tumors. Reduced expression of <i>OTUD4</i> and <i>CYLD</i> is associated with poor prognosis in patients with melanoma. Together, these results reveal an OTUD4–CYLD–BCL3 regulatory axis in melanoma, in which OTUD4 stabilizes CYLD and inhibits BCL3 activity.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

OTUD4 stabilizes CYLD and counteracts BCL3 K63-linked polyubiquitination to suppress melanoma progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月28日

查看全文
  • Yuming He,
  • Lin Miao,
  • Yunfang Deng,
  • Yuyao Xue,
  • Zhaohui Liu,
  • Zhiming Sun,
  • Chujing He,
  • Hao Feng,
  • Jiabing Li,
  • Yuqiao Cai,
  • Yaoyu Gu,
  • Ke Li,
  • Yu Zhao

摘要

Melanoma is a highly aggressive malignancy in which dysregulated ubiquitin-dependent signaling contributes to tumor progression. OTUD4 is frequently downregulated in melanoma, but the functional significance of this alteration remains unclear. Here, we identify OTUD4 as a dual-mode deubiquitinase that suppresses melanoma progression by coordinating K48- and K63-linked polyubiquitination. OTUD4 directly binds and stabilizes CYLD by counteracting K48-linked polyubiquitination, whereas it independently binds BCL3 and counteracts BCL3 K63-linked polyubiquitination. OTUD4 depletion promotes BCL3 ubiquitination and nuclear translocation in melanoma cells, leading to increased melanoma cell proliferation and tumor growth in clonogenic and xenograft assays. Clinically, expression of OTUD4 and CYLD progressively decreases from normal skin through benign nevi to melanoma, with a further reduction in highly metastatic tumors. Reduced expression of OTUD4 and CYLD is associated with poor prognosis in patients with melanoma. Together, these results reveal an OTUD4–CYLD–BCL3 regulatory axis in melanoma, in which OTUD4 stabilizes CYLD and inhibits BCL3 activity.